BACKGROUND: Therapies for peanut allergy (PNA) are urgently needed. Food Allergy Herbal Formula-2 (FAHF-2) has profound therapeutic effects in a murine PNA model and is safe for food-allergic adults in clinical trials. However, the large FAHF-2 pill-load is not conducive to clinical studies in children. Thus, refining FAHF-2 to decrease pill-load is essential for the inclusion of children in clinical trials and to facilitate studying FAHF-2 as a clinically useful botanical drug. OBJECTIVES: Testing long-term efficacy and safety of a butanol-purified extract of FAHF-2 (B-FAHF-2) in a murine model of PNA, and to explore its immunological mechanisms of action. METHODS: FAHF-2 was purified by butanol extraction. C3H/HeJ mice with established PNA received the first course of B-FAHF-2 at 6 mg, twice daily for 7 weeks (PNA/B-FAHF-2) or water (PNA/sham) and were then challenged immediately after completing the treatment and six more times every 1-2 months post-treatment up to week 50. Mice then received a second course of B-FAHF-2 treatment at week 52 and were challenged at week 65. In vivo and in vitro immunological effects on T, B and mast cells were also determined. RESULTS: Butanol purification reduced the volume of the effective dose ∼5-fold. All PNA/B-FAHF-2 mice were completely protected from PN anaphylaxis until the fifth challenge after the first course of treatment, as compared with PNA/sham mice. Partial protection persisted up to 50 weeks. A second treatment course restored complete protection. B-FAHF-2 significantly suppressed Th2 cytokine, IgE and histamine levels in vivo, and showed direct inhibition of Th2, IgE-producing B cells and mast cell activation in vitro. B-FAHF-2 had a high margin of safety. CONCLUSION AND CLINICAL RELEVANCE: B-FAHF-2 produced long-lasting protection against PN anaphylaxis for approximately half of the murine life span without side-effects. B-FAHF-2 exhibited direct effects on multiple food allergy effector cells.
BACKGROUND: Therapies for peanut allergy (PNA) are urgently needed. Food Allergy Herbal Formula-2 (FAHF-2) has profound therapeutic effects in a murine PNA model and is safe for food-allergic adults in clinical trials. However, the large FAHF-2 pill-load is not conducive to clinical studies in children. Thus, refining FAHF-2 to decrease pill-load is essential for the inclusion of children in clinical trials and to facilitate studying FAHF-2 as a clinically useful botanical drug. OBJECTIVES: Testing long-term efficacy and safety of a butanol-purified extract of FAHF-2 (B-FAHF-2) in a murine model of PNA, and to explore its immunological mechanisms of action. METHODS: FAHF-2 was purified by butanol extraction. C3H/HeJmice with established PNA received the first course of B-FAHF-2 at 6 mg, twice daily for 7 weeks (PNA/B-FAHF-2) or water (PNA/sham) and were then challenged immediately after completing the treatment and six more times every 1-2 months post-treatment up to week 50. Mice then received a second course of B-FAHF-2 treatment at week 52 and were challenged at week 65. In vivo and in vitro immunological effects on T, B and mast cells were also determined. RESULTS:Butanol purification reduced the volume of the effective dose ∼5-fold. All PNA/B-FAHF-2mice were completely protected from PN anaphylaxis until the fifth challenge after the first course of treatment, as compared with PNA/sham mice. Partial protection persisted up to 50 weeks. A second treatment course restored complete protection. B-FAHF-2 significantly suppressed Th2 cytokine, IgE and histamine levels in vivo, and showed direct inhibition of Th2, IgE-producing B cells and mast cell activation in vitro. B-FAHF-2 had a high margin of safety. CONCLUSION AND CLINICAL RELEVANCE: B-FAHF-2 produced long-lasting protection against PN anaphylaxis for approximately half of the murine life span without side-effects. B-FAHF-2 exhibited direct effects on multiple food allergy effector cells.
Authors: Julie Wang; Sangita P Patil; Nan Yang; Jimmy Ko; Joohee Lee; Sally Noone; Hugh A Sampson; Xiu-Min Li Journal: Ann Allergy Asthma Immunol Date: 2010-07 Impact factor: 6.347
Authors: X M Li; D Serebrisky; S Y Lee; C K Huang; L Bardina; B H Schofield; J S Stanley; A W Burks; G A Bannon; H A Sampson Journal: J Allergy Clin Immunol Date: 2000-07 Impact factor: 10.793
Authors: Kamal D Srivastava; Jacob D Kattan; Zhong Mei Zou; Jing Hua Li; Libang Zhang; Sylvan Wallenstein; Joseph Goldfarb; Hugh A Sampson; Xiu-Min Li Journal: J Allergy Clin Immunol Date: 2005-01 Impact factor: 10.793
Authors: Donald Y M Leung; Hugh A Sampson; John W Yunginger; A Wesley Burks; Lynda C Schneider; Cornelis H Wortel; Frances M Davis; John D Hyun; William R Shanahan Journal: N Engl J Med Date: 2003-03-10 Impact factor: 91.245
Authors: Julie Wang; Stacie M Jones; Jacqueline A Pongracic; Ying Song; Nan Yang; Scott H Sicherer; Melanie M Makhija; Rachel G Robison; Erin Moshier; James Godbold; Hugh A Sampson; Xiu-Min Li Journal: J Allergy Clin Immunol Date: 2015-06-01 Impact factor: 10.793
Authors: K D Srivastava; Y Song; N Yang; C Liu; I E Goldberg; A Nowak-Węgrzyn; H A Sampson; X-M Li Journal: Clin Exp Allergy Date: 2017-05-15 Impact factor: 5.018